Clinical trial NCT04073888: Study of the Spermatic Characteristics of Patients With Fabry Disease
Official title: Study of the Spermatic Characteristics of Patients With Fabry Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fabry Disease
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2019-08-29
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.The main objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.

Detailed description: Fabry disease is a lysosomal storage burden of X-linked genetic transmission due to alpha-galactosidase deficiency. This enzyme deficiency causes deposits of globotriaosylceramide in virtually all cell types of the body. The majority of hemizygous men develop a severe multisystemic disease dominated by renal failure, neurological and cardiac involvement. There is a specific treatment based on enzyme replacement therapy.

The incidence of Fabry disease is estimated between 1/60000 and 1/3500 in the general population.

Infertility in Fabry disease is poorly documented. Only a few cases have been reported, from alteration of spermogram to azoospermia. The identification of deposits suggestive of Gb3 in light microscopy and electron microscopy at the level of the genital tract argues in favor of the attack of this device. The low prevalence of Fabry disease requires a cross-sectional multicenter study to determine the frequency of alterations in sperm characteristics, their impact on fertility, and the possible effect of substitution therapy, in order to establish appropriate measures. adequate preventive measures.

The objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.The main objective of this project is to estimate the prevalence of spermatic abnormalities in patients with Fabry disease.

Eligibility criteria: Inclusion Criteria:

* male patients with Fabry disease regardless of the clinical form of the disease; treated with enzyme replacement therapy or not (from the initial diagnosis). The definite diagnosis of Fabry disease will be established on the deficit of the activity of alpha galactosidase A (\<12%). A molecular genetic study is desirable but not mandatory,
* patients aged 18 to 65,
* giving their free and informed consent to participate, after information on the research.

Exclusion Criteria:

* persons placed under the protection of justice,
* unaffiliated or non-beneficiary subject of a social security scheme.

Primary outcomes:
measure: volume (ml) of sperm
timeFrame: At Day 1
measure: pH of sperm
timeFrame: At Day 1
measure: Count (million / ml) of spermatozoids
timeFrame: At Day 1
measure: Mobility (%) and mobility type of spermatozoa according to WHO classification of spermatozoids
timeFrame: At Day 1
measure: Total number of spermatozoa in one ejaculate
timeFrame: At Day 1
measure: Total number of progressive motile spermatozoa
timeFrame: At Day 1
measure: Existence of leukospermia yes/no
timeFrame: At Day 1
measure: % of typical forms of spermatozoids
timeFrame: At Day 1
measure: Multiple Anomalies Index (MAI) of spermatozoids
timeFrame: At Day 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Bordeaux
name: Alice PAPAXANTHOS, Dr
role: PRINCIPAL_INVESTIGATOR
References: